EMPA-KIDNEY Trial Contribution — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — EMPA-KIDNEY demonstrated kidney benefit of Empagliflozin across a broader CKD population including patients with lower levels of albuminuria (ACR <300 mg/g) and those without diabetes – expanding the evidence base beyond DAPA-CKD
EMPA-KIDNEY (2022) broadened the SGLT2i evidence in CKD by including patients with lower albuminuria (ACR as low as 0 mg/g if eGFR 20-45) and demonstrating benefit in this broader population. While DAPA-CKD required ACR ≥200 mg/g, EMPA-KIDNEY showed that patients with lower albuminuria and lower eGFR also benefited. This supported the KDIGO 2024 recommendation to suggest (2B) SGLT2i for patients with eGFR 20-45 even with ACR <200 mg/g. Together, CREDENCE, DAPA-CKD, and EMPA-KIDNEY form the SGLT2i-CKD evidence triad.
Reference: EMPA-KIDNEY – NEJM 2023; KDIGO 2024 – CKD